

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT	iii
ABSTRACT (ENGLISH)	iv
ABSTRACT (THAI)	vi
LIST OF TABLES	x
LIST OF ILLUSTRATIONS	xi
ABBREVIATIONS	xii
CHAPTER 1 Introduction	1
CHAPTER 2 Literature review	3
2.1 Carbamazepine in clinical practice	3
2.2 Pharmacology of carbamazepine	4
2.2.1 Mechanisms of action	4
2.2.2 Pharmacokinetics	6
2.3 Drug interactions	10
2.4 Side effects	11
2.5 Therapeutic drug monitoring of anticonvulsants	11
2.6 Salivary therapeutic drug monitoring for anticonvulsants	12
2.6.1 Physiology of the saliva glands	14
2.6.2 Pharmacokinetic principles of drug distribution in saliva	15
2.6.3 Diseases and drugs influencing salivary secretion	17
2.7 Relationship between plasma-saliva concentration of carbamazepine and clinical effect	18
2.8 Methodology	22

	Page
CHAPTER 3 Materials and Methods	23
3.1 Materials and instruments	23
3.2 Apparatus	24
3.3 HPLC system	24
3.4 Method	25
3.4.1 Subject	25
3.4.2 Sample collection techniques	25
3.4.3 Extraction and assay procedure	25
3.4.4 Standard curve	26
3.4.5 Accuracy and precision of the assay procedure	26
3.4.6 Stability of carbamazepine in frozen plasma and saliva	26
3.4.7 Data analysis	26
3.4.8 Application to the patients	27
CHAPTER 4 Results	28
4.1 Precision of assay procedure	29
4.2 Accuracy of assay procedure	34
4.3 Stability of carbamazepine in frozen plasma and saliva	35
4.4 The correlation between plasma and saliva carbamazepine concentration	36
4.5 Application to the patients	38
CHAPTER 5 Conclusion and Discussion	41
REFERENCES	43
APPENDIX A	55
CURRICULUM VITAE	61

LIST OF TABLES

Table		Page
1	Advantages and disadvantages of using samples for therapeutic drug monitoring	13
2	Studies of saliva and blood concentration of CBZ	20
3	Intraday variation of analysis method for carbamazepine in plasma	30
4	Intraday variation of analysis method for carbamazepine in saliva	31
5	Interday variation of analysis method for carbamazepine in plasma	32
6	Interday variation of analysis method for carbamazepine in saliva	33
7	Percent recoveries of analysis method for carbamazepine in plasma	34
8	Percent recoveries of analysis method for carbamazepine in saliva	34
9	Stability of carbamazepine in frozen plasma	35
10	Stability of carbamazepine in frozen saliva	35
11	The individual data of application to patient	39

LIST OF ILLUSTRATIONS

Figure	Page
1 Structural formula of carbamazepine	3
2 Major pathways of metabolism of carbamazepine in man	8
3 Plasma clearance carbamazepine (CBZ)-D ₄ when given as a single oral dose at different times before and during maintenance CBZ treatment in three patients with recently discovered epilepsy. Multiple dosing was started on day 5.	9
4 Plasma concentration of CBZ (◊) and CBZ- D ₄ (●) in 2 alcoholic patients, who were treated with CBZ during the withdrawal period.	9
5 Time course of salivary CBZ levels in a patient receiving 200 mg of the drug twice daily	19
6 Chromatogram of A) plasma carbamazepine and B) saliva carbamazepine (RT ≈ 3.2 min) and propylparaben (RT ≈ 4.0 min) as internal standard	28
7 Intraday variation of analysis method for carbamazepine in plasma	30
8 Intraday variation of analysis method for carbamazepine in saliva	31
9 Interday variation of analysis method for carbamazepine in plasma	32
10 Interday variation of analysis method for carbamazepine in saliva	33
11 The correlation between saliva and plasma CBZ concentration of all 50 volunteers	37

ABBREVIATIONS

°C	degree celcius
CBZ	carbamazepine
CBZ-E	carbamazepine-10,11-epoxide
CBZ-H	tran-10,11-dihydroxy-10,11-dihydro-carbamazepine
EIA	enzyme immunoassay
FIA	fluorescence immunoassay
FPIA	fluorescence polarization immunoassay
GLC	gas-liquid chromatography
HPLC	high-performance liquid chromatography
L/kg	liter per kilogram
μcl	microliter
μmole	micromole
mg	milligram
ml	milliliter
ng	nanogram
nm	nanometer
[PCBZ]	plasma carbamazepine concentration
PP	propylparaben
rpm	round per minute
[SCBZ]	saliva carbamazepine concentration
t _½	elimination half-life
UV	ultraviolet